News Conference News NY Valves 2025 MitraClip Safe and Effective in Non-COAPT-Like Patients: EXPANDed Yael L. Maxwell July 03, 2025
Presentation THT 2025 Impella 5.5 Support for Heart Failure-Related Cardiogenic Shock and 1-Year Survival: Insights From a Multi-Center Registry Presenter: Jacob Abraham February 12, 2025
Presentation THT 2025 Introduction of Guideline Directed Medical Therapy (GDMT) in Acute Myocardial Infarction (AMI) Shock Patients Supported by Impella 5.5 Presenter: Kanika Mody February 12, 2025
Presentation THT 2025 Debate: Impella 5.5 Should Be Used to Optimize PTs Pre LVAD Presenter: Katherine Wood February 12, 2025
Presentation THT Abstracts 2025 Acute Hemodynamic Effects of Impella 5.5 in Cardiogenic Shock and Decompensated Heart Failure on Hepatorenal Function Presenter: Gabrielle Daso February 11, 2025
Presentation THT Abstracts 2025 Introduction of Guideline Directed Medical Therapy (GDMT) in Acute Myocardial Infarction (AMI) Shock Patients Supported by Impella 5.5 February 11, 2025
Presentation THT Abstracts 2025 Cardiac Recovery in Cardiogenic Shock Patients Treated With Impella 5.5 Presenter: Alexis Barnes February 11, 2025
Presentation THT 2025 Characteristics and Outcomes of Patients With Impella 5.5 Complicated by Stroke: A Cardiogenic Shock Working Group Analysis Presenter: Anthony Carnicelli February 11, 2025
Presentation THT 2025 Cardiac Recovery in Cardiogenic Shock Patients Treated With Impella 5.5 Presenter: Alexis Barnes February 11, 2025
Presentation THT 2025 Acute Hemodynamic Effects of Impella 5.5 in Cardiogenic Shock and Decompensated Heart Failure on Hepatorenal Function Presenter: Gabrielle Daso February 11, 2025
Presentation THT 2025 Management of Clinically Stable Patients With Impella 5.5 on a Cardiac Stepdown Unit Is Associated With Low Adverse Event Rates and Lower Hospital Costs Presenter: Anthony Carnicelli February 11, 2025
Presentation THT 2025 Impella 5.5: A GameChanger for Cardiogenic Shock Presenter: Jerome Crowley February 11, 2025